Dr. Andrew Huberman

However, it does appear that at least for adults who are

not suffering from particular psychiatric challenges, namely forms of psychosis, right?

This is real.

I mean, one in 100 people experiences schizophrenic symptoms, et cetera.

It's a very high number if you think about it.

Certain forms of bipolar depression that the clinical trials on psychedelics, and here I'm assuming when you say hallucinogens, you're referring to psychedelics, are very, very compelling.

The psychiatric community is now being forced to look at these data because the data are very compelling.

What do we know about these data?

And yes, I've participated in two such clinical trials, one on high dose psilocybin, high dose meaning more than two grams taken twice.

By the way, this is with the support of

medically trained therapists and the use of psychedelics such as psilocybin, mostly psilocybin, not so much LSD.

Do you know why most of the trials are on psilocybin and not LSD?

I do, but I'm curious if, you know, it's not to, what's that?

Right?

It's a long ride.

So the thing about psilocybin is that the sort of journey, the trip is somewhere on the order of anywhere from three to seven hours, which can fit into a reasonable workday for a technician, clinician.

And LSD can be many, many hours longer.

The kind of Mount Everest of

Psychedelics, which is under investigation by a colleague of mine at Stanford School of Medicine, Nolan Williams, is Ibogaine, Iboga, which is 22 hours long.

It has cardiac effects.